The HPV vaccine has one of the most thoroughly studied safety profiles of any vaccine in use today. With more than 135 million doses distributed in the United States alone, the CDC confirms that no adverse events have been found to occur at higher-than-expected rates following vaccination, with the sole exception of fainting, which is common after any injection in adolescents. The World Health Organization’s Global Advisory Committee on Vaccine Safety goes further, calling HPV vaccines “extremely safe.”
What Side Effects Are Common
The most frequent side effects are the ones you’d expect from any shot: soreness, swelling, and redness at the injection site. These reactions are temporary and typically resolve within a day or two. Some people also experience a mild headache, fever, or fatigue afterward.
Fainting is the one reaction that stands out compared to other vaccines, though it’s tied to the age group receiving the shot rather than the vaccine itself. Adolescents are more prone to fainting after any injection due to anxiety or stress responses. For this reason, you’ll be asked to sit or lie down for about 15 minutes after getting the shot so staff can monitor you.
Severe allergic reactions (anaphylaxis) are extremely rare, occurring at a rate of roughly 1.7 cases per million doses. That’s in line with other routine vaccines.
Serious Safety Concerns That Have Been Investigated
Over the years, several potential safety signals have been flagged and rigorously investigated. These include Guillain-Barré syndrome (a nerve condition causing muscle weakness), seizures, stroke, and blood clots. None of these were confirmed as being linked to the HPV vaccine after detailed review.
Two conditions have drawn particular attention: CRPS, a chronic pain condition, and POTS, a disorder that causes dizziness and rapid heart rate upon standing. The European Medicines Agency conducted a dedicated review of both. It found that the rates of these conditions in vaccinated girls were no different from the rates expected in unvaccinated girls of the same age. In the general population, roughly 150 per million girls and young women aged 10 to 19 develop CRPS each year, and at least 150 per million develop POTS, regardless of vaccination status. The WHO’s safety committee reached the same conclusion: no causal link exists between the HPV vaccine and either condition.
What About Fertility?
Claims that the HPV vaccine causes premature ovarian insufficiency, a condition where the ovaries stop functioning normally before age 40, have circulated online for years. A large study using Kaiser Permanente health records tracked nearly 200,000 female patients aged 11 to 34 over eight years. Out of that entire group, researchers confirmed just 46 cases of unexplained ovarian insufficiency. Only one of those patients had received the HPV vaccine beforehand, and it was administered 23 months before any symptoms appeared.
The statistical analysis found no elevated risk. The hazard ratio for ovarian insufficiency after HPV vaccination was 0.30, meaning vaccinated individuals were actually less likely to be diagnosed, though the numbers were too small to draw directional conclusions. The bottom line: the data do not support a connection between the HPV vaccine and fertility problems. The WHO has also noted that inadvertent HPV vaccination during pregnancy has shown no adverse outcomes for either mother or baby.
What’s in the Vaccine
Gardasil 9, the HPV vaccine currently used in the United States, contains virus-like particles made from proteins that mimic the outer shell of HPV. These particles cannot cause infection because they contain no viral DNA. Each 0.5 mL dose includes approximately 225 micrograms of aluminum, used as an adjuvant to strengthen the immune response. For context, that’s less aluminum than what a typical infant absorbs from breast milk or formula in a single day.
The vaccine also contains yeast protein and polysorbate 80, a common food emulsifier. You should not get the vaccine if you have a known severe allergy to yeast, polysorbate 80, or the aluminum adjuvant used in the formulation. A previous allergic reaction to an earlier dose of Gardasil or Gardasil 9 is also a reason to skip further doses.
How Clinical Trials Measured Safety
In the pivotal clinical trials for Gardasil 9, over 15,700 participants received the vaccine and were followed for safety outcomes. Serious adverse events of any kind were reported in 2.3% of that group. The comparison group, which received the earlier version of Gardasil rather than a true placebo, reported serious adverse events at a rate of 2.5%. The rates were essentially the same, indicating that the newer vaccine didn’t introduce additional safety risks beyond what was already established.
These trials were large enough to detect rare events, and since the vaccine’s approval, ongoing surveillance systems have continued to monitor safety in the real world. The CDC’s Vaccine Safety Datalink, a collaboration with eight major healthcare organizations, actively tracks outcomes in vaccinated populations. After reviewing all post-licensure data, no new adverse events of concern have been identified.
What the Vaccine Prevents
Understanding the safety profile matters most in context of what the vaccine does. HPV vaccination in adolescence leads to a 40% reduction in cervical precancers and more than an 80% reduction in overall cervical cancer risk. HPV also causes cancers of the throat, anus, penis, vagina, and vulva, so the protective benefit extends well beyond the cervix.
Cervical cancer kills over 300,000 people worldwide each year. The vaccine works best when given before any exposure to the virus, which is why it’s recommended at ages 11 to 12, though it can be given as early as 9 and is approved for adults up to age 45. The protection has proven durable, with studies showing sustained immune responses more than a decade after vaccination.